The latest investigational drugs for patients with allergic rhinitis
The management toward AR should fully consider the phenotypic and endotypic characteristics of the patients and develop stepwise, comprehensive, and personalized care pathways that combine pharmacotherapy, AIT, and biologics. Further studies are needed to validate long-term efficacy and safety and optimize precision medicine approaches.
Authors
- Luo Zhang (ORCID: https://orcid.org/0000-0002-2817-7874)
- Dandan Fang
- Yuan Zhang
Institutions
- Capital University (US)
- Capital Medical University (CN)
- Beijing Institute of Neurosurgery (CN)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1080/13543784.2025.2612328
- Primary Topic
- Allergic Rhinitis and Sensitization
- Type
- article
- Field-Weighted Citation Impact
- 0.00